A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CDZ173 in Patients With Primary Sjögren's Syndrome
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2018
At a glance
- Drugs Leniolisib (Primary)
- Indications Sjogren's syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 16 Jun 2018 Primary endpoint (EULAR Sjgrens Syndrome Patient Reported Intensity (ESSPRI) change from baseline) has not been met, according to results presented at the 19th Annual Congress of the European League Against Rheumatism.
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism.
- 08 Jun 2017 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History